Table 1. Vaccine Effectiveness against Infection and against Disease in Qatar.
Type of Infection or Disease | PCR-Positive Persons | PCR-Negative Persons | Effectiveness (95% CI)* | ||
---|---|---|---|---|---|
Vaccinated | Unvaccinated | Vaccinated | Unvaccinated | ||
number of persons | percent | ||||
Infection | |||||
PCR-confirmed infection with the B.1.1.7 variant† | |||||
After one dose | 892 | 18,075 | 1241 | 17,726 | 29.5 (22.9–35.5) |
≥14 days after second dose | 50 | 16,354 | 465 | 15,939 | 89.5 (85.9–92.3) |
PCR-confirmed infection with the B.1.351 variant‡ | |||||
After one dose | 1329 | 20,177 | 1580 | 19,926 | 16.9 (10.4–23.0) |
≥14 days after second dose | 179 | 19,396 | 698 | 18,877 | 75.0 (70.5–78.9) |
Disease § | |||||
Severe, critical, or fatal disease caused by the B.1.1.7 variant | |||||
After one dose | 30 | 468 | 61 | 437 | 54.1 (26.1–71.9) |
≥14 days after second dose | 0 | 401 | 20 | 381 | 100.0 (81.7–100.0) |
Severe, critical, or fatal disease caused by the B.1.351 variant | |||||
After one dose | 45 | 348 | 35 | 358 | 0.0 (0.0–19.0) |
≥14 days after second dose | 0 | 300 | 14 | 286 | 100.0 (73.7–100.0) |
Severe, critical, or fatal disease caused by any SARS-CoV-2 | |||||
After one dose | 139 | 1,966 | 220 | 1,885 | 39.4 (24.0–51.8) |
≥14 days after second dose | 3 | 1,692 | 109 | 1,586 | 97.4 (92.2–99.5) |
Vaccine effectiveness was estimated with the use of a test-negative case–control study design,2 with persons found positive by polymerase-chain-reaction (PCR) testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serving as cases in the analysis and those found negative by PCR serving as controls. PCR-positive and PCR-negative persons were matched one to one according to age, sex, nationality, and reason for PCR testing. Vaccine effectiveness was calculated as described by Jackson and Nelson2 (see the Supplementary Appendix).
A B.1.1.7 infection was identified as an S gene “target failure” in an analysis conducted with the TaqPath COVID-19 Combo Kit platform (Thermo Fisher Scientific), with the criteria of a PCR cycle threshold value no higher than 30 for the genes encoding both the nucleocapsid protein (N) and ORF1ab but a negative outcome for the gene encoding the spike protein (S) applied. The median date of vaccination was March 1 for PCR-positive persons and February 28 for the matched PCR-negative persons.
Because only B.1.351 and B.1.1.7 viruses were identified in viral genome sequencing in Qatar after March 7, 2021, the criteria used to identify a B.1.351 infection involved the complement of the criterion for S that was used to identify a B.1.1.7 infection — that is, any infection with a cycle threshold value no higher than 30 for the genes encoding N, ORF1ab, and S between March 8 and March 31 was regarded as a B.1.351 infection. The median date of vaccination was March 7 for the PCR-positive persons and March 1 for the matched PCR-negative persons.
Effectiveness against severe, critical, or fatal disease caused by PCR-confirmed SARS-CoV-2 infection was analyzed. The B.1.1.7 and B.1.351 variants were dominant in Qatar during the study period. Severe, critical, and fatal coronavirus disease 2019 (Covid-19) were defined on the basis of the World Health Organization criteria3 for classifying SARS-CoV-2 infection severity and Covid-19–related death.